{"id":18767,"date":"2021-01-12T16:09:44","date_gmt":"2021-01-12T15:09:44","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=18767"},"modified":"2021-01-12T16:09:44","modified_gmt":"2021-01-12T15:09:44","slug":"biogeneration-ventures-bgv-iv-fund-closes-at-e140-million","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/","title":{"rendered":"BioGeneration Ventures BGV IV fund closes at \u20ac140 million"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of BGV IV at \u20ac140 million ($170 million).&nbsp; BGV IV was oversubscribed, with strong investor demand in the fund.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">At the final close, LPs included the global pharma company, Eli Lilly and Company, and Novo Holdings (led by its venture arm, Novo Ventures), a world-leading life science investor. They joined other corporate and institutional investors including Bristol Myers Squibb, Schroder Adveq, Industriens Pension, KfW Capital and the European Investment Fund (with the support of the European Commission\u2019s Investment Plan for Europe and of the Netherlands National Promotional Institution Invest-NL).&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">BGV is now one of the largest biotech investors in Europe dedicated to early-stage ventures and company creation, with over \u20ac250 million ($300 million) in assets under management.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The investment focus of the fourth fund is to seek innovations that have a truly differentiated scientific foundation, supported by convincing experimental data. These innovations must be compelling and stand out in the global scientific arena, and have the potential to have a substantial healthcare impact.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Edward van Wezel, BGV\u2019s Managing Partner\u00a0said: <em>\u201cProgressing early-stage projects from discovery to clinical proof-of-concept requires a breadth of experience that founding teams often do not have from the outset. This is where BGV\u2019s team collective experience is a key differentiator, with its extensive network and experience spanninginvestment, life sciences, business development, and commercial operations. With this fund closing at \u20ac140 million, we are well positioned to support our portfolio companies with both increased financial capacity and our strong, expanding international network.\u201d<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;The BGV IV fund will continue the successful investment strategy of previous funds and has already made four investments. BGV\u2019s aim is to build new companies, around either single assets or technology platforms, with the goal of creating transformational new medicines and also creating significant returns for its LPs. BGV\u2019s strategy is supported by its longstanding collaboration with Forbion, providing a platform across early- to late-stage companies.&nbsp;&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;Portfolio successes include <a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2016\/astrazeneca-completes-transaction-for-majority-equity-stake-investment-in-acerta-pharma-01022016.html\">Acerta Pharma, which was acquired by AstraZeneca<\/a> for up to $7bn and <a href=\"https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2019\/calquence-granted-us-breakthrough-therapy-designation-for-chronic-lymphocytic-leukaemia-14082019.html\">whose lead product Calquence\u00ae is now approved and marketed in the US<\/a>, and <a href=\"https:\/\/www.statenbiotech.com\/news#:~:text=Under%20the%20exclusive%20option%20agreement,up%20to%20430%20million%20euros.\">Staten Biotechnology, which signed a \u20ac430 million exclusive option deal with Novo Nordisk<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00a0Other companies in the current BGV portfolio include NorthSea Therapeutics, Azafaros, Varmx, and Confo Therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source: BGV (<a href=\"https:\/\/www.biogenerationventures.com\/news-releases\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/\">Press release<\/a>)<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of BGV IV at \u20ac140 million ($170 million).&nbsp; BGV IV was oversubscribed, with strong investor demand in the fund.&nbsp; At the final close, LPs included the global pharma company, Eli Lilly and Company, and Novo Holdings (led by its venture arm, Novo [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[43],"tags":[],"class_list":["post-18767","post","type-post","status-publish","format-standard","hentry","category-innovatieklimaat"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioGeneration Ventures BGV IV fund closes at \u20ac140 million - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioGeneration Ventures BGV IV fund closes at \u20ac140 million - hollandbio\" \/>\n<meta property=\"og:description\" content=\"BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of BGV IV at \u20ac140 million ($170 million).&nbsp; BGV IV was oversubscribed, with strong investor demand in the fund.&nbsp; At the final close, LPs included the global pharma company, Eli Lilly and Company, and Novo Holdings (led by its venture arm, Novo [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-12T15:09:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"HollandBIO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"HollandBIO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/\"},\"author\":{\"name\":\"HollandBIO\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\"},\"headline\":\"BioGeneration Ventures BGV IV fund closes at \u20ac140 million\",\"datePublished\":\"2021-01-12T15:09:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/\"},\"wordCount\":401,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Innovatieklimaat\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/\",\"name\":\"BioGeneration Ventures BGV IV fund closes at \u20ac140 million - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2021-01-12T15:09:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioGeneration Ventures BGV IV fund closes at \u20ac140 million\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\",\"name\":\"HollandBIO\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioGeneration Ventures BGV IV fund closes at \u20ac140 million - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/","og_locale":"en_US","og_type":"article","og_title":"BioGeneration Ventures BGV IV fund closes at \u20ac140 million - hollandbio","og_description":"BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, announces the closing of BGV IV at \u20ac140 million ($170 million).&nbsp; BGV IV was oversubscribed, with strong investor demand in the fund.&nbsp; At the final close, LPs included the global pharma company, Eli Lilly and Company, and Novo Holdings (led by its venture arm, Novo [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/","og_site_name":"hollandbio","article_published_time":"2021-01-12T15:09:44+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"HollandBIO","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"HollandBIO","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/"},"author":{"name":"HollandBIO","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea"},"headline":"BioGeneration Ventures BGV IV fund closes at \u20ac140 million","datePublished":"2021-01-12T15:09:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/"},"wordCount":401,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Innovatieklimaat"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/","name":"BioGeneration Ventures BGV IV fund closes at \u20ac140 million - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2021-01-12T15:09:44+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/biogeneration-ventures-bgv-iv-fund-closes-at-e140-million\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"BioGeneration Ventures BGV IV fund closes at \u20ac140 million"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea","name":"HollandBIO"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/18767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=18767"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/18767\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=18767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=18767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=18767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}